



The Current State of Absence Epilepsy: Can We Have Your Attention?

Jeffrey R. Tenney, MD, PhD¹ and Tracy A. Glauser, MD²

¹Assistant Professor of Pediatric and Neurology, Comprehensive Epilepsy Center, Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

²Professor of Pediatric and Neurology, Director Comprehensive Epilepsy Center Comprehensive Epilepsy Center, Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Address correspondence to: Jeffrey R. Tenney, MD, PhD Comprehensive Epilepsy Center, Division of Neurology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH, 45229. E-mail: jeffrey.tenney@cchmc.org

Absence seizures are common within many different epilepsies and span all the ages. Even though absence seizures were described more than three centuries ago advances associated with its classification, pathophysiology, genetics, treatment, prognosis, and associated co-morbidities continue to be made.

Absence seizures are common in many forms of pediatric and adult epilepsies and are the hallmark seizure type in two epilepsy syndromes—childhood absence epilepsy and juvenile absence epilepsy. The term “absence” was first used to describe seizures in 1705 and was reported as pyknolepsy (“heaped up, closely packed, aggregated attacks”) in the early 20th century (1). Even though more than 300 years have passed since its first description, there continue to be new advances in our understanding of the classification, treatment, pathophysiology, and prognosis of absence seizures and the syndromes they help define.

Clinical Characteristics and Electroencephalography

Typical Absence Seizures

The classical clinical manifestations of typical absence seizures are a transient impairment of consciousness (with abrupt onset and offset) accompanied by one or more other features such as staring, behavioral arrest, eyelid fluttering, or hand/face automatisms (2). The ictal EEG of a typical absence seizure demonstrates generalized spike and wave complexes that are > 2.5 Hz, typically 3–4.5 Hz (3) and lasting ≥ 3 seconds (4, 5). The “3 second” rule is clinically reasonable and provides an objective EEG measure to detect absence seizures when clinical seizures are hard to identify (6). A recent study of 339 seizures in 47 children with absence seizures reported an average ictal duration of 9.4 ± 7 seconds (range 1–44 seconds) (7). Typical absence seizures have a bimodal distribution for age of onset; the first peak at 6–7 years (childhood) with a second peak near 12 years of age (juvenile) (8). The ictal discharges in the juvenile form are slightly less rhythmic and may be of faster frequency (9).

Atypical Absence Seizures

Atypical absence seizures have less abrupt onset and offset, more pronounced changes in tone, variable impairments of consciousness, and tend to last longer than typical absences (10). They are most likely to occur during drowsiness and are not provoked by hyperventilation or photic stimulation (11). Atypical absence seizures have a characteristic interictal EEG pattern with generalized slow (1.5–2.5 Hz) spike and wave complexes that are irregular, asymmetrical, and lower amplitude. The ictal pattern is diffuse, irregular, slow spike and wave complexes that can be associated with irregular diffuse fast activity (5).

Absence with Special Features

The 2010 revised ILAE Report on Terminology and Classification recognized two additional types of absence seizures that have special features: myoclonic absence seizures and eyelid myoclonia with absence (EMA) (12). Seizures described as EMA are characterized as prominent jerking of the eyelids with upward deviation of the eyes, often triggered by eye closure. The ictal EEG pattern for EMA has been described as 3–6 Hz generalized polyspike and wave complexes with occasional paroxysmal bursts in the occipital head regions which can precede the generalized discharges (13).

Syndrome Classification

Childhood Absence Epilepsy (CAE)

CAE is a childhood epilepsy syndrome occurring in 10–17% of all childhood onset epilepsy, making it the most common pediatric epilepsy syndrome (14, 15). Females are more affected than males (16). The ILAE definition of CAE includes very frequent (several to many per day) absences in children of school age (peak manifestation of 6–7 years), and an EEG with bilateral, synchronous, and symmetrical spike-wave discharges at 3 Hz (17). In 2005, an ILAE Task Force for Classification and Terminology added inclusion criteria for age of onset between 4 and 10 years, with a peak between 5 and 7 years (18). It has



since become clear that there is a rare subset of patients with onset of absence seizures under the age of 4 years, a proportion of who have glucose transporter type 1 deficiency (19). In addition, the upper age cutoff of 10 years is arbitrary, and there are some who feel that this age limit should not be used to determine which patients to categorize as CAE (3). Instead, it may be reasonable to classify patients with pyknoleptic (very frequent daily) absences, regardless of age, as CAE and there is some indication that onset of a pyknoleptic pattern of absences after age 11 years is unusual (8).

Juvenile Absence Epilepsy (JAE)

Although juvenile absence epilepsy (JAE) also has absences as the main seizure type, the absences of JAE have a less severe impairment of consciousness (even though the duration of electrographic discharges can be longer) and lack a pyknoleptic pattern (i.e., only one or a few absences daily) (20). Most cases begin between 10 and 17 years of age (8). However, at the lower age limit, there is a great deal of overlap with CAE, and it is not clear which criteria—age of onset, pyknoleptic versus non-pyknoleptic events—distinguish between these syndromes for children with onset of absences between 10 to 12 year of age (21). A distinguishing factor from CAE is that generalized tonic clonic seizures (GTCS) are much more common in JAE and have been reported to eventually occur in almost 80% of patients (22).

Jeavons Syndrome

EMA can occur with idiopathic, cryptogenic, or symptomatic epilepsies. The idiopathic form is referred to as Jeavons syndrome, and EMA in this syndrome usually occurs following eyelid closure. Onset is in childhood, and all patients are photosensitive (23). It is unclear whether Jeavons syndrome should be classified as a type of absence epilepsy or as a myoclonic epilepsy, given its prominent eyelid myoclonia.

Pathophysiology

Since the early studies of Jasper and Williams, controversy has ensued regarding whether the structure that produces and controls the spike-wave discharges responsible for absence epilepsy is in the cortex, thalamus, or both (24, 25). Many now accept the unifying hypothesis that the spike-wave discharges of absence seizures are probably produced via reciprocally connected neurons in the thalamus and cortex (26).

Studies of absence seizures using EEG-fMRI have shown activation patterns within the frontal and parietal cortices and thalamus, although the relative amounts of signal increases and decreases have varied (27–29). MEG provides a different approach due to submillisecond time scale temporal resolution (30). A study of children with medically refractory absence epilepsy using MEG showed that there is focal, rather than diffusely generalized, cortical activity prior to the onset of SWDs (31). Similar MEG findings in patients with newly diagnosed and untreated CAE have shown that the area of maximal activity varies depending on frequency bandwidth (Figure 1).

Future studies will investigate whether seizure generator location varies among patients, and correlates with either differential comorbidities, differential response to treatment, or differential outcomes.

Genetics

The importance of genetics in the development of absence epilepsies has been recognized for more than 70 years (32). Recent work has underscored the genetic complexity of absence epilepsy. Mutations in genes that code for subunits of GABA receptors, calcium channels and novel non-ion channel proteins have been identified as associated with absence epilepsy but only in small populations of affected patients (33). The unifying mechanistic link between the identified GABA and calcium channel mutations is through disruptive effects on the thalamocortical network (33). Given its complexity, a variety of genetic techniques (e.g., whole-exome and whole-genome sequencing, epigenetic studies, copy number variation, etc.) will be needed to better understand the genetics underlying absence epilepsy.

Treatment

Childhood Absence Epilepsy

Prior to 2010, a total of six, short duration, small randomized controlled trials (RCTs) had examined ethosuximide (ESM), valproic acid (VPA), and lamotrigine (LTG) initial monotherapy in children with absence epilepsy. Due to multiple methodological limitations, none of these RCTs met the criteria for either a Class I or II study, providing insufficient evidence to inform clinical practice (34). In 2010, an NIH-funded 446 patient, 32-center double-blind, randomized, comparative controlled clinical trial examined the efficacy and tolerability of ESM, VPA, and LTG (6). At the week 16–20 visit, subjects on ESM (53%) and VPA (58%) had significantly higher freedom from failure rates than LTG (29%, $p < 0.001$ for both comparisons); subjects on ethosuximide had significantly less attentional dysfunction compared to subjects on valproic acid (33% vs. 49%, $p = 0.03$). This combination of findings implied that ESM is the optimal initial monotherapy for CAE (6). However, despite being the “winner” at the week 16–20 visit, ESM therapy failed in 47% of subjects (14% due to seizures, 24% due to intolerable side effects, 13% withdrew from study) (6). The recent identification of antiepileptogenic effects of ESM in the WAG/Rij model of absence epilepsy (35, 36) reinforces the need to determine the long-term impact of initial therapy in this large prospectively followed cohort.

Juvenile Absence Epilepsy

No randomized-controlled double-blind trials have been conducted in Juvenile Absence Epilepsy. Separate expert opinion surveys in the US and Europe found VPA and LTG to be the top initial treatment choice for JAE (as they treat both absences and tonic-clonic seizures) (37, 38). Second line (or later) treatments with evidence of modest efficacy for JAE have included ESM, amantadine, and the ketogenic diet (39, 40).

Jeavons Syndrome

Many reports indicate that EMA of idiopathic type or Jeavons syndrome is resistant to pharmacologic treatment (3). Avoidance of seizure precipitants can be important and non-pharmacologic treatments for photosensitive patients, such as wearing special glasses, can be beneficial (41). The most commonly used medications for Jeavons syndrome are VPA, ESM, benzodiazepines (BZDs), levetiracetam (LEV), and phenobarbital (PB).




FIGURE 1. Four children with newly diagnosed and untreated childhood absence epilepsy were recruited and thirteen absence seizures were recorded during the MEG sessions. (A) Time-frequency analysis showed significant spectral power density in the 1–20 Hz, 20–70 Hz, and 70–150 Hz bandwidths. (B) Source localization using a sLORETA algorithm demonstrated consistent localization preferentially in the parietal region for activity at 1–20 Hz and localization preferentially to the lateral frontal region at 20–70 Hz.

Outcome and Prognosis

Childhood Absence Epilepsy

Remission rates for CAE, based on epidemiologic cohort studies, range from 21%–74% (42–57). In five prospective cohort studies, the proportion of seizure free subjects were 57%–74% (42, 44–46, 50, 51). Although labeled a “benign” syndrome, the clinical course of CAE is variable and remission rates are far lower than in other classic benign idiopathic epilepsies such as Benign Rolandic Epilepsy (58).

Multiple studies report that GTCs ultimately develop in roughly 40% (range 35%–60%) of children with absence seizures at onset (45, 59–62). GTCs often occur 5 to 10 years after the onset of the absence seizures (45), between 8–15 years old (60, 61, 63). Risk factors include onset of absence seizures after 8 years old, male sex, lack of response to initial therapy and therapy with only an anti-absence drug (8, 62, 64).

Accidental injury is common; 20% of young adults with CAE were reported to suffer an injury during an absence seizure. The risk of accidental injury resulting from an absence seizure is estimated to be 3% per person year (56, 65).

Juvenile Absence Epilepsy

The long-term prognosis for those with JAE is unclear. There is some evidence that patients with only absences have a much greater chance of achieving complete seizure control

than those with absences plus GTCs (66). JAE is thought to persist into adulthood at higher rates than CAE. Neurophysiological differences between areas of seizure onset and spread may account for some of the differences in medication responsiveness and long-term prognosis for CAE and JAE.

Jeavons Syndrome

The outcome and prognosis for Jeavons syndrome is poorly understood. There is some evidence that GTCs, either light-induced or spontaneous, will occur in most patients over the long term (67). Jeavons syndrome is thought to be a lifelong disorder, resistant to medical treatment (3).

Comorbidities

Children with CAE have elevated rates of adverse behavioral, psychiatric, language, and cognitive comorbidities (including attentional problems, anxiety, depression, social isolation, and low self-esteem) (68–70). Small series have reported difficulties in the areas of visual attention and visuospatial skills (71, 72), verbal learning and memory (73), and reductions in language abilities (74). The 2010 Childhood Absence Epilepsy study detected overall normal cognition, but 35% of subjects had pre-treatment attentional deficits that did not abate even when seizures were controlled (6).



Conclusion

Although absence seizures are common within many different epilepsies and span all ages, there are still many unanswered questions. Despite many advances during the past decade, there is still much to learn. For example, should criteria for CAE or JAE syndrome classification be based on age at onset, frequency of seizures, or a yet undetermined biomarker? What is the true long-term medication responsiveness and prognosis of CAE and JAE? Many clinical and electrographic features of CAE and JAE are similar, especially at the time of initial diagnosis, but prognosis can vary from complete seizure freedom to medically intractable, lifelong seizures. Are there neurophysiologic differences in the brain networks responsible for generating seizures in these groups of patients? The ongoing Childhood Absence Epilepsy Study aims to address many of these issues for CAE, but the JAE questions remain unanswered. A better understanding of the pathophysiology and course of absence seizures and its syndromes is critical to developing therapies that improve these children's quality of life and potentially the lives of all patients with generalized epilepsies.

References

1. Adie WJ. Pyknolepsy: A form of epilepsy in children, with a good prognosis. *Proc R Soc Med* 1924;17(Neural Sect):19–25.
2. Penry JK, Dreifuss FE. Automatism associated with the absence of petit mal epilepsy. *Arch Neurol* 1969;21:142–149.
3. Panayiotopoulos CP. Typical absence seizures and related epileptic syndromes: Assessment of current state and directions for future research. *Epilepsia* 2008;49:2131–2139.
4. Frank LM, Enlow T, Holmes GL, Manasco P, Concannon S, Chen C, Womble G, Casale EJ. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. *Epilepsia* 1999;40:973–979.
5. Holmes GL, McKeever M, Adamson M. Absence seizures in children: Clinical and electroencephalographic features. *Ann Neurol* 1987;12:268–273.
6. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. *N Engl J Med* 2010;362:790–799.
7. Sadleir LG, Farrell K, Smith S, Connolly MB, Scheffer IE. Electroclinical features of absence seizures in childhood absence epilepsy. *Neurology* 2006;67:413–418.
8. Loiseau P, Duche B, Pedespan JM. Absence epilepsies. *Epilepsia* 1995;36:1182–1186.
9. Loddenkemper TBS, Serratosa JM, Berkovic SF. Idiopathic generalized epilepsy syndromes of childhood and adolescence. In: *The Treatment of Epilepsy*. (Wyllie EGA, Lachhwani DK, eds) Philadelphia: Lippincott Williams & Wilkins, 2006:399–400.
10. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. *Epilepsia* 1981;22:489–501.
11. Epstein MA, Duchowny M, Jayakar P, Resnick TJ, Alvarez LA. Altered responsiveness during hyperventilation-induced EEG slowing: A non-epileptic phenomenon in normal children. *Epilepsia* 1994;35:1204–1207.
12. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW, Moshe SL, Nordli D, Plouin P, Scheffer IE. Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia* 2010;51:676–685.
13. Senbil N, Soyer O, Turanly G, Gurer YK. Fixation-off sensitivity and generalized epileptic EEG induced by eyes closed. *Pediatr Neurol* 2006;35:363–366.
14. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B. How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis. *Epilepsia* 2000;41:1269–1275.
15. Jallon P, Loiseau P, Loiseau J. Newly diagnosed unprovoked epileptic seizures: Presentation at diagnosis in CAROLE study. Coordination Active du Réseau Observatoire Longitudinal de l'Epilepsie. *Epilepsia* 2001;42:464–475.
16. Camfield CS, Camfield PR, Gordon K, Wirrell E, Dooley JM. Incidence of epilepsy in childhood and adolescence: A population-based study in Nova Scotia from 1977 to 1985. *Epilepsia* 1996;37:19–23.
17. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. *Epilepsia* 1989;30:389–399.
18. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J Jr. Epileptic seizures and epilepsy: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia* 2005;46:470–472.
19. Mullen SA, Suls A, De Jonghe P, Berkovic SF, Scheffer IE. Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency. *Neurology* 2010;75:432–440.
20. Dreifuss FE. Classification of epilepsies in childhood. In: *Pediatric Epilepsy: Diagnosis and Therapy*. (Pellock JM, Bourgeois BF, eds.) New York: Demos Medical Publishing, 2001:74–75.
21. Reutens DC, Berkovic SF. Idiopathic generalized epilepsy of adolescence: Are the syndromes clinically distinct? *Neurology* 1995;45:1469–1476.
22. Wolf P, Inoue Y. Therapeutic response of absence seizures in patients of an epilepsy clinic for adolescents and adults. *J Neurol* 1984;231:225–229.
23. Striano S, Capovilla G, Sofia V, Romeo A, Rubboli G, Striano P, Trenite DK. Eyelid myoclonia with absences (Jeavons syndrome): A well-defined idiopathic generalized epilepsy syndrome or a spectrum of photosensitive conditions? *Epilepsia* 2009;50:15–19.
24. Williams D. A study of thalamic and cortical rhythms in petit mal. *Brain* 1953;76:50–69.
25. Jasper HH, Droogleeveer-Fortuyn, J. Experimental studies on the functional anatomy of petit epilepsy. *Res Publ Assoc Res Nerv Ment Dis* 1947;26:272–298.
26. Snead OC. Basic mechanisms of generalized absence seizures. *Ann Neurol* 1995;37:146–157.
27. Carney PW, Masterton RA, Harvey AS, Scheffer IE, Berkovic SF, Jackson GD. The core network in absence epilepsy. Differences in cortical and thalamic BOLD response. *Neurology* 2010;75:904–911.
28. Moeller F, LeVan P, Muhle H, Stephani U, Dubeau F, Siniatchkin M, Gotman J. Absence seizures: Individual patterns revealed by EEG-fMRI. *Epilepsia* 2010;51:2000–2010.
29. Berman R, Negishi M, Vestal M, Spann M, Chung MH, Bai X, Purcaro M, Motelow JE, Danielson N, Dix-Cooper L, Enev M, Novotny EJ, Constable RT, Blumenfeld H. Simultaneous EEG, fMRI, and behavior in typical childhood absence seizures. *Epilepsia* 2010;51:2011–2022.
30. Hillebrand A, Barnes GR. A quantitative assessment of the sensitivity of whole-head MEG to activity in the adult human cortex. *Neuroimage* 2002;16:638–650.



31. Westmijse I, Ossenblok P, Gunning B, van Luijtelaar G. Onset and propagation of spike and slow wave discharges in human absence epilepsy: A MEG study. *Epilepsia* 2009;50:2538–2548.
32. Lennox WG. The heredity of epilepsy as told by relatives and twins. *J Am Med Assoc* 1951;146:529–536.
33. Yalcin O. Genes and molecular mechanisms involved in the epileptogenesis of idiopathic absence epilepsies. *Seizure* 2012;21:79–86.
34. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T. ILAE treatment guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. *Epilepsia* 2006;47:1094–1120.
35. Russo E, Citraro R, Scicchitano F, De Fazio S, Di Paola ED, Constanti A, De Sarro G. Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. *Epilepsia* 2010;51:1560–1569.
36. Blumenfeld H, Klein JP, Schridde U, Vestal M, Rice T, Khera DS, Bashyal C, Giblin K, Paul-Laughinghouse C, Wang F, Phadke A, Mission J, Agarwal RK, Englot DJ, Motelow J, Nersesyan H, Waxman SG, Levin AR. Early treatment suppresses the development of spike-wave epilepsy in a rat model. *Epilepsia* 2008;49:400–409.
37. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: Expert opinion, 2005. *J Child Neurol* 2005;20:S1–S5, S59–60.
38. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. *Epileptic Disord* 2007;9:353–412.
39. Fattore C, Boniver C, Capovilla G, Cerminara C, Citterio A, Coppola G, Costa P, Darra F, Vecchi M, Perucca E. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. *Epilepsia* 2011;52:802–809.
40. Groomes LB, Pyzik PL, Turner Z, Dorward JL, Goode VH, Kossoff EH. Do patients with absence epilepsy respond to ketogenic diets? *J Child Neurol* 2011;26:160–165.
41. Appleton RE, Panayiotopoulos CP, Acomb BA, Beirne M. Eyelid myoclonia with typical absences: An epilepsy syndrome. *J Neurol Neurosurg Psychiatry* 1993;56:1312–1316.
42. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B, Ebrahimi N. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. *Epilepsia* 2001;42:1553–1562.
43. Bouma PA, Westendorp RG, van Dijk JG, Peters AC, Brouwer OF. The outcome of absence epilepsy: A meta-analysis. *Neurology* 1996;47:802–808.
44. Fois A, Malandrini F, Mostardini R. Clinical experiences of petit mal. *Brain Dev* 1987;9:54–59.
45. Loiseau P, Pestre M, Dartigues JF, Commenges D, Barberger-Gateau C, Cohadon S. Long-term prognosis in two forms of childhood epilepsy: Typical absence seizures and epilepsy with rolandic (centrotemporal) EEG foci. *Annals of neurology* 1983;13:642–648.
46. Sato S, Dreifuss FE, Penry JK, Kirby DD, Palesch Y. Long-term follow-up of absence seizures. *Neurology* 1983;33:1590–1595.
47. Bartolomei F, Roger J, Bureau M, Genton P, Dravet C, Viallat D, Gastaut JL. Prognostic factors for childhood and juvenile absence epilepsies. *Eur Neurol* 1997;37:169–175.
48. Chaix Y, Daquin G, Monteiro F, Villeneuve N, Laguitton V, Genton P. Absence epilepsy with onset before age three years: A heterogeneous and often severe condition. *Epilepsia* 2003;44:944–949.
49. Grosso S, Galimberti D, Vezzosi P, Farnetani M, Di Bartolo RM, Bazzotti S, Morgese G, Balestri P. Childhood absence epilepsy: Evolution and prognostic factors. *Epilepsia* 2005;46:1796–1801.
50. Sillanpaa M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. *New Engl J Med* 1998;338:1715–1722.
51. Sillanpaa M, Jalava M, Shinnar S. Epilepsy syndromes in patients with childhood-onset seizures in Finland. *Pediatr Neurol* 1999;21:533–537.
52. Sinclair DB, Unwala H. Absence epilepsy in childhood: Electroencephalography (EEG) does not predict outcome. *J Child Neurol* 2007;22:799–802.
53. Trinko E, Baumgartner S, Unterberger I, Unterrainer J, Luef G, Haberlandt E, Bauer G. Long-term prognosis for childhood and juvenile absence epilepsy. *J Neurol* 2004;251:1235–1241.
54. Wirrell E, Camfield C, Camfield P, Dooley J. Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy. *Epilepsia* 2001;42:760–763.
55. Wirrell EC, Camfield CS, Camfield PR, Gordon KE, Dooley JM. Long-term prognosis of typical childhood absence epilepsy: Remission or progression to juvenile myoclonic epilepsy [see comments]. *Neurology* 1996;47:912–918.
56. Wirrell EC, Camfield PR, Camfield CS, Dooley JM, Gordon KE. Accidental injury is a serious risk in children with typical absence epilepsy [see comments]. *Arch Neurol* 1996;53:929–932.
57. Yoshinaga H, Ohtsuka Y, Tamai K, Tamura I, Ito M, Ohmori I, Oka E. EEG in childhood absence epilepsy. *Seizure* 2004;13:296–302.
58. Shinnar S, Berg AT, Moshe SL, Kang H, O'Dell C, Alemany M, Goldensohn ES, Hauser WA. Discontinuing antiepileptic drugs in children with epilepsy: A prospective study. *Ann Neurol* 1994;35:534–545.
59. Currier RD, Kooi KA, Saidman LJ. Prognosis of "Pure" Petit Mal; a Follow-up Study. *Neurology* 1963;13:959–967.
60. Livingston S, Torres I, Pauli LL, Rider RV. Petit mal epilepsy. Results of a prolonged follow-up study of 117 patients. *JAMA* 1965;194:227–232.
61. Charlton MH, Yahr MD. Long-term follow-up of patients with petit mal. *Arch Neurol* 1967;16:595–598.
62. Oller-Daurella L, Sanchez M. Evolucion de las ausencias tipicas. *Rev Neurol (Barcelona)* 1981;9:81–102.
63. Dieterich E, Baier WK, Doose H, Tuxhorn I, Fichsel H. Longterm follow-up of childhood epilepsy with absences. I. Epilepsy with absences at onset. *Neuropediatrics* 1985;16:149–154.
64. Loiseau P. Childhood absence epilepsy. In: *Epileptic Syndromes in Infancy, Childhood and Adolescence*. (Roger J, Bureau M, Dreifuss FE, Wolf P, eds.) London: John Libbey Eurotext, 1985:106–120.
65. Deonna T. Childhood absence epilepsy and accidents. *Arch Neurol* 1997;54:1063.
66. Tovia E, Goldberg-Stern H, Shahar E, Kramer U. Outcome of children with juvenile absence epilepsy. *J Child Neurol* 2006;21:766–768.
67. Giannakodimos S, Panayiotopoulos CP. Eyelid myoclonia with absences in adults: A clinical and video-EEG study. *Epilepsia* 1996;37:36–44.
68. Wirrell EC, Camfield CS, Camfield PR, Dooley JM, Gordon KE, Smith B. Long-term psychosocial outcome in typical absence epilepsy. Sometimes a wolf in sheeps' clothing. *Arch Pediatr Adolesc Med* 1997;151:152–158.
69. Caplan R, Siddarth P, Stahl L, Lanphier E, Vona P, Gurbani S, Koh S, Sankar R, Shields WD. Childhood absence epilepsy: Behavioral, cognitive, and linguistic comorbidities. *Epilepsia* 2008;49:1838–1846.
70. Vega C, Guo J, Killory B, Danielson N, Vestal M, Berman R, Martin L, Gonzalez JL, Blumenfeld H, Spann MN. Symptoms of anxiety and depression in childhood absence epilepsy. *Epilepsia* 2011;52:e70–74.



71. Levav M, Mirsky AF, Herault J, Xiong L, Amir N, Andermann E. Familial association of neuropsychological traits in patients with generalized and partial seizure disorders. *J Clin Exp Neuropsychol* 2002;24:311–326.
72. Pavone P, Bianchini R, Trifiletti RR, Incorpora G, Pavone A, Parano E. Neuropsychological assessment in children with absence epilepsy. *Neurology* 2001;56:1047–1051.
73. Henkin Y, Sadeh M, Kivity S, Shabtai E, Kishon-Rabin L, Gadoth N. Cognitive function in idiopathic generalized epilepsy of childhood. *Dev Med Child Neurol* 2005;47:126–132.
74. Vanasse CM, Beland R, Carmant L, Lassonde M. Impact of childhood epilepsy on reading and phonological processing abilities. *Epilepsy Behav* 2005;7:288–296.



American Epilepsy Society

Epilepsy Currents Journal

Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



American Epilepsy Society

Epilepsy Currents Journal

Disclosure of Potential Conflicts of Interest

Section #1 Identifying Information

1. Today's Date: 11/8/2012
2. First Name Jeffrey Last Name Tenney Degree M.D., Ph.D.
3. Are you the Main Assigned Author? Yes No

If no, enter your name as co-author:

4. Manuscript/Article Title: The Current State of Absence Epilepsy: Can We Have Your Attention?
5. Journal Issue you are submitting for: December, 2012 (I think)

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship just add rows to this table.

Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**
1. Grant	<input checked="" type="checkbox"/>				
2. Consulting fee or honorarium	<input checked="" type="checkbox"/>				
3. Support for travel to meetings for the study or other purposes	<input checked="" type="checkbox"/>				
4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	<input checked="" type="checkbox"/>				
5. Payment for writing or reviewing the manuscript	<input checked="" type="checkbox"/>				
6. Provision of writing assistance, medicines, equipment, or administrative support.	<input checked="" type="checkbox"/>				
7. Other	<input checked="" type="checkbox"/>				

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section #3 Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

Type of relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**
1. Board membership	<input checked="" type="checkbox"/>				
2. Consultancy	<input checked="" type="checkbox"/>				
3. Employment	<input checked="" type="checkbox"/>				
4. Expert testimony	<input checked="" type="checkbox"/>				
5. Grants/grants pending	<input checked="" type="checkbox"/>				
6. Payment for lectures including service on speakers bureaus	<input checked="" type="checkbox"/>				
7. Payment for manuscript preparation.	<input checked="" type="checkbox"/>				
8. Patents (planned, pending or issued)	<input checked="" type="checkbox"/>				
9. Royalties	<input checked="" type="checkbox"/>				
10. Payment for development of educational presentations	<input checked="" type="checkbox"/>				
11. Stock/stock options	<input checked="" type="checkbox"/>				
12. Travel/accommodations/meeting expenses unrelated to activities listed.**	<input checked="" type="checkbox"/>				
13. Other (err on the side of full disclosure)	<input checked="" type="checkbox"/>				

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- No other relationships/conditions/circumstances that present a potential conflict of interest.
 Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
Epilepsy Currents Editorial Board



American Epilepsy Society

Epilepsy Currents Journal

Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



American Epilepsy Society

Epilepsy Currents Journal

Disclosure of Potential Conflicts of Interest

Section #1 Identifying Information

1. Today's Date: June 11, 2013
2. First Name Tracy Last Name Glauser Degree MD
3. Are you the Main Assigned Author? Yes No

If no, enter your name as co-author: Tenney

4. Manuscript/Article Title: The Current State of Absence Epilepsy: Can We Have Your Attention?

5. Journal Issue you are submitting for: May/June

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking "No" or providing the requested information. If you have more than one relationship just add rows to this table.

Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**
1. Grant	<input type="checkbox"/>	No	Yes	NINDS	U01 045911 Childhood Absence Epilepsy: Rx, PK-PD- Pharmacogenetics
2. Consulting fee or honorarium	<input checked="" type="checkbox"/>				
3. Support for travel to meetings for the study or other purposes	<input checked="" type="checkbox"/>				
4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	<input checked="" type="checkbox"/>				
5. Payment for writing or reviewing the manuscript	<input checked="" type="checkbox"/>				
6. Provision of writing assistance, medicines, equipment, or administrative support.	<input checked="" type="checkbox"/>				
7. Other	<input checked="" type="checkbox"/>				

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section #3 Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

Type of relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**
1. Board membership	<input checked="" type="checkbox"/>				
2. Consultancy	<input type="checkbox"/>	Yes	No	Supernus Sunovion Eisai ucb Pharma, inc Lundbeck Questcor Upsher Smith AssureRx GeneDx	Advisory Board
3. Employment	<input checked="" type="checkbox"/>				
4. Expert testimony	<input checked="" type="checkbox"/>				
5. Grants/grants pending	<input type="checkbox"/>	No	Yes	NINDS	NeuroNEXT, EPGP, FEBSTAT, FIRST study, MiPEDS
6. Payment for lectures including service on speakers bureaus	<input type="checkbox"/>	Yes	No	Supernus Questcor	
7. Payment for manuscript preparation.	<input checked="" type="checkbox"/>				
8. Patents (planned, pending or issued)	<input type="checkbox"/>	Yes	Yes	AssureRx	
9. Royalties	<input type="checkbox"/>	Yes	Yes	AssureRx	
10. Payment for development of educational presentations	<input type="checkbox"/>	Yes	No	Supernus Questcor	
11. Stock/stock options	<input type="checkbox"/>	Yes	Yes	AssureRx	
12. Travel/accommodations/meeting expenses unrelated to activities listed.**	<input checked="" type="checkbox"/>				
13. Other (err on the side of full disclosure)	<input checked="" type="checkbox"/>				

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- No other relationships/conditions/circumstances that present a potential conflict of interest.
 Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
Epilepsy Currents Editorial Board